Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 6;13:200. doi: 10.1186/s13578-023-01151-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 7 — High miR-181a levels in OvCa FFPE tissues are associated with olaparib resistance. A Quantification of miR-181a levels by RT-qPCR comparing parental and cisplatin- and olaparib-resistant (Resistant) OV81.2 and OV231 cell lines (Student’s t-test). B Quantification of miR-181a levels by RT-qPCR comparing control Clone 1 (CTRL), miR-181a KO Clone 7 (C7), and miR-181a KO Clone 16 (C16) cell lines (One-way ANOVA). C Drug sensitivity assays comparing control Clone 1, miR-181a KO C7, and miR-181a KO C16 cell lines treated with different concentrations of olaparib (One-way ANOVA and Sidak’s multiple comparisons test). *p < 0.05, **p < 0.01, ***p < 0.001. D Representative images of miR-181a ISH in pre-treatment (Pre-Tx) and post-treatment (Post-Tx) paired tissues from OvCa patients. Images of negative control probes (Negative CTRL), positive control probes (Positive CTRL), Pre-Tx, and Post-Tx paired FFPE tissues from OvCa patient #1 (P01). E Quantification of miR-181a levels (dots/nuclei) in Pre-Tx and Post-Tx paired tissues from OvCa patients (Student’s t-test). *p < 0.05, **p < 0.01, ***p < 0.001. Cell viability assays were performed in triplicates. F–I Correlation between miR-181a levels and cisplatin (F), rucaparib (G), olaparib (H), talazoparib (I) drug activity in the BC and OvCa cell lines obtained from CCLE and GDSC BRCA datasets (Pearson’s correlation coefficient)